ClinicalTrials.gg
RecruitingNCT06654414Updated Oct 8, 2026

Adapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke

An interventional study of PRIDE QUIT and Enhanced Treatment As Usual (ETAU) in Smoking Cessation, Depression and Anxiety, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Smoking Cessation by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Smoking Cessation · Massachusetts General Hospital.

Planned enrollment
18th of 27
100 · median 131
Started
2024
with 3 others
No phase
15 of 27
3 open now
Registered
25th of 27
by date

Among the 27 studies in Smoking Cessation by Massachusetts General Hospital, this one is the 18th largest by planned enrollment, is one of 4 that started in 2024, is one of 15 with no phase, and was the 25th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

4 of the 27 studies in Smoking Cessation by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Smoking Cessation by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.

Read the detailed description

Despite the substantial decrease in smoking prevalence over the past 50 years, persistent and significant disparities in tobacco use remain among clinical and non-clinical populations of adults who smoke. Cigarette use among clinical populations, including patients with HIV and those with significant developmental stress, ranges from approximately 40-70%, compared with 10-12% among non-clinical populations. Clinical populations with HIV and developmental stressors also show dramatically higher rates of e-cigarette use relative to non-clinical populations (26.5% vs. 5.5% in some samples of adults who smoke). Adults managing HIV and developmental stressors may be particularly vulnerable to the consequences of tobacco use through increased heart disease risk, and smoking may hinder recovery from HIV and other related illnesses. Differential responses to developmental stressors, the stress of managing HIV and its treatment, and co-occurring clinical concerns such as anxiety and depression further contribute to these differences in tobacco use. Anxiety and depression are major impediments to smoking cessation and are more prevalent among people with developmental stress and people living with HIV than in non-clinical samples. Anxiety symptoms co-occur with smoking at high rates and significantly impair cessation success. Similarly, depressed mood and major depressive disorder-both more common among people who smoke than among those who do not-are associated with reduced odds of cessation. The high prevalence of anxiety and depression among clinical populations of adults who smoke therefore leaves these individuals particularly vulnerable to cessation difficulties. A tailored smoking cessation intervention that builds cognitive-behavioral skills for cessation while also reducing stress and associated anxiety and depression symptoms has strong potential to mitigate tobacco use. We propose to adapt an existing smoking cessation intervention, QUIT, to address the unique needs of adults with developmental stress who smoke. In focus groups with individuals who use tobacco (N ≤ 32) and providers (N ≤ 8), we will explore the ways in which stress and associated anxiety/depression compromise cessation, and identify content in the current version of QUIT that does and does not meet participants' needs. Providers will also comment on anticipated implementation barriers. Following the ADAPT-ITT model, these qualitative data will inform adaptation of the intervention. We will then test the feasibility and acceptability of the adapted intervention (QUIT 2.0) in a pilot randomized controlled trial (RCT; N = 60), assessing for signals of clinically meaningful change in biologically verified 7-day point-prevalence abstinence, average number of cigarettes smoked, and stress, anxiety, depression, and distress tolerance. If QUIT 2.0 is feasible and acceptable, it will be ready for a hybrid efficacy/effectiveness trial. We will also include a non-randomized, retrospective comparison group-matched on age, sex, and average number of cigarettes smoked per day in the past week-consisting of adults with HIV who completed the original, un-adapted intervention (QUIT 1.0).

03

Conditions studied

  • Smoking Cessation
  • Depression
  • Anxiety
  • Nicotine Dependence
  • Gender Minority Stress

Keywords

  • Smoking Cessation
  • Smoking
  • Tobacco Use
  • Tobacco Use Disorder
  • Substance-Related Disorder
  • Nicotine
  • Anxiety
  • Depression
  • Transgender Individuals
  • Gender Expansive Individuals
  • Gender Minority Stress
  • Distress Tolerance
  • Quitting
  • Cognitive Behavioral Therapy
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 18+
  2. self-reported difference between sex assigned at birth and gender identity
  3. current use of combustible cigarettes (defined as self-reported 5 combustible cigarettes per day in any week in the past month and a carbon monoxide [CO] expired-air reading of ≥8ppm) OR current use of nicotine-containing e-cigarettes (defined by saliva cotinine level of ≥30ng/mL) with use of combustible cigarettes (5 cigarettes per day in any week in the past month)
  4. desire to stop using tobacco products (defined by ≥5 on the Motivational Aspects of Smoking Cessation Questionnaire)
  5. English-speaking.

Exclusion criteria

Exclusion Criteria:

  1. unable to provide
  2. current interfering untreated or unstable major health condition (e.g., bipolar, current psychosis)
  3. current use of psychotherapy for smoking cessation
  4. participation in Aim 1a procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PRIDE QUIT

    Participants in this adapted intervention arm (n=30) will receive empirically-based, Cognitive-Behavioral therapy-based strategies, tailored for transgender and gender diverse (TGD) individuals, which aims to help participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. This intervention group will receive a general educational session (session 0) followed by 5 active weekly sessions and a booster session 4 weeks after T2 (approx. 14 weeks post-baseline), with the quit day set between sessions 3 and 4.

    Behavioral: PRIDE QUIT

  • Active comparator
    Enhanced Treatment As Usual (ETAU)

    Participants in this arm (n=30) will receive enhanced treatment as usual at Fenway Health. These participants will attend one session (brief counseling), will come to the clinic for weekly assessments only, and referral to the Quit Line.

    Behavioral: Enhanced Treatment As Usual (ETAU)

Interventions

  • BehavioralPRIDE QUIT

    This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will receive a pre-randomization general educational session (session 0) followed by 5 weekly sessions and a booster sessions 4 weeks after T2, with the quit day set between sessions 3 and 4.

  • BehavioralEnhanced Treatment As Usual (ETAU)

    Brief counseling, American Cancer Society cessation resources (palm card with information on how to access the American Cancer Society website) after pre-randomization educational session (session 0,) the option of nicotine replacement therapy, and referral to the Quit Line.

06

What researchers measure

Primary outcomes

  1. Acceptability

    Acceptability will be assessed via the Client Satisfaction Questionnaire-4 (CSQ-4) which will be completed after every other treatment session. Items are scored using a 4-point Likert scale with (1) quite dissatisfied; (2) dissatisfied; (3) satisfied; (4) quite satisfied. The questions include: (1) To what extent has our program met your needs?; (2) Have the services you received helped you to deal more effectively with your problems?; (3) In an overall, general sense, how satisfied are you with the service you have received?; (4) If you were to seek help again, would you come back to our program? The intervention will be deemed acceptable if at least 75% of the participants rate 4+ items on the acceptability questionnaires with a 3 or a 4 on the Likert-style scale.

    Time frame: Through the end of treatment intervention, approximately 6 weeks

  2. Feasibility of the Intervention

    Feasibility of the intervention is a primary outcome measure that will be calculated based on three assessments: (1) interventionist fidelity to the protocol (via a review of 10% of session recordings to determine whether key themes were addressed), (2) session attendance, and (3) participant retention at follow-up. Feasibility will be demonstrated if at least (1) 80% of the reviewed sessions address all key themes, (2) 75% of the participants attend at least half of all treatment sessions; and (3) 70% of the participants complete the 3-month follow-up.

    Time frame: Through participants' enrollment, approximately 6 months

Secondary outcomes

  1. 7-Day Point Prevalence Abstinence

    7-day point prevalence abstinence will be verified via expired-air carbon monoxide (CO) assessed with a Smokerlyzer, with 5ppm indicating abstinence (24 hours to two weeks). Because CO expired-air readings are significantly lower among users of e-cigarettes, abstinence for those using mostly e-cigarettes at baseline will be verified by cotinine assessment via a NicConfirm Mouth Swab Cotinine test (30 ng/ml indicates abstinence of 1-4 days).

    Time frame: At the 3-month follow-up and 6-month follow-up

  2. Gender Minority Stress

    Gender minority stress will be measured via the internal experience subscales of the Gender Minority Stress and Resilience Measure (GMSRM), including non-affirmation of gender identity, internalized transphobia, negative expectations, nondisclosure, community connectedness, and pride. Participants respond to each statement using a five-point Likert scale ranging from "Strongly Disagree" to "Strongly Agree."

    Time frame: At baseline assessment, 3-month follow-up, and 6-month follow-up

  3. Average Number of Cigarettes Smoked Per Day in the Past Week

    Average number of cigarettes smoked per day in the past week, assessed via self-report.

    Time frame: At baseline assessment, end of each treatment session (weekly for 5 weeks post-baseline), 3-month follow-up, and 6-month follow up

  4. Anxiety Symptoms

    1\. Anxiety symptoms will be assessed by the Generalized Anxiety Disorder 7-item (GAD-7). Likert style: Not at all (0) to Nearly every day (3); scores range from 0 to 21, with higher scores indicating greater levels of symptomatology. 2. Participants will also be asked to rate their anxiety on a scale from 0 to 10, with 0 being no anxiety and 10 being the worst possible anxiety.

    Time frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up

  5. Depression Symptoms

    1\. Depressive symptoms will be assessed by the Patient Health Questionnaire 8-item scale (PHQ-8). Likert style: Not at all (0) to Nearly every day (3); scores range from 0 to 24, with higher scores indicating greater levels of symptomatology. 2. Participants will also be asked to rate their depressive symptoms on a scale from 0 to 10, with 0 being no depressed mood and 10 being the worst possible depressed mood.

    Time frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up.

  6. Distress Tolerance

    Distress tolerance will be assessed using the Distress Tolerance Scale (DTS). Likert style: Strongly Agree (1) to Strongly Disagree (5); scores range from 16-80, with higher scores indicating greater levels of distress tolerance.

    Time frame: At baseline assessment, 3-month follow-up, and 6-month follow-up

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Based on the approved DSMP, we plan to only share deidentified data via a controlled access repository. No PHI, recordings, or unconsented human data will be made available to other investigators.

Supporting information: Study protocol, Statistical analysis plan

Time frame: According to the approved DSMP, data will be uploaded at 6-monthly intervals.

Access criteria: Any shared data will be stored in the NIH-approved controlled access repository, Cancer Data Service (CDS). Other qualified investigators, with authorized CDS access will have access to this data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 30 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Mar 2025 → Mar 2027 and completion Mar 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 23, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Mar 31, 2027was Mar 2025
CompletionEst.
Aug 31, 2027was Mar 2025
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Terminated→Recruiting Reason for stopping removed
changed Oct 8, 2026
Sites
3 sites changed recruiting status (2 now active, not recruiting, 1 now recruiting)
Show 3 sites
  • Massachusetts General Hopsital · Boston, United Statesno status→Active, not recruiting
  • Boston University - Charles River Campus · Boston, United Statesno status→Active, not recruiting
  • Fenway Health · Boston, United Statesno status→Recruiting
Oct 8, 2026
Primary completion
Mar 18, 2025→Mar 31, 2027
Oct 8, 2026
Study completion
Mar 21, 2025→Aug 31, 2027
Oct 8, 2026
Enrollment
3 (actual)→100 (estimated)
Oct 8, 2026
Eligibility
2 inclusion criteria added, 1 removed; 1 exclusion criterion edited, 2 added
What changed in the criteria
Inclusion criteria
  • Removedcurrent use of combustible cigarettes OR recent use of combustible cigarettes (defined as at least 5 cigarettes-per-day at some point within the past 6 months) OR current use of nicotine-containing e-cigarettes with use of combustible cigarettes in the past 6 months (defined as 5 cigarettes-per-day)
  • Addedcurrent use of combustible cigarettes (defined as self-reported 5 combustible cigarettes per day in any week in the past month and a carbon monoxide [CO] expired-air reading of ≥8ppm) OR current use of nicotine-containing e-cigarettes (defined by saliva cotinine level of ≥30ng/mL) with use of combustible cigarettes (5 cigarettes per day in any week in the past month)
  • Addeddesire to stop using tobacco products (defined by ≥5 on the Motivational Aspects of Smoking Cessation Questionnaire)
Exclusion criteria
  • Editedcurrent interfering untreated or unstable major health condition that is event during screening (e.g., active maniabipolar, current psychosis)
  • Addedcurrent use of psychotherapy for smoking cessation
  • Addedparticipation in Aim 1a procedures.
Oct 8, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAcceptabilityThrough the end of treatment intervention, approximately 10 weeks → Through the end of treatment intervention, approximately 6 weeks
  • DescriptionAcceptability: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
2 edited, 2 time frame changed, 2 added, 4 removed
What changed in the outcomes
  • EditedAverage Number of Cigarettes Smoked Per Day In Thein the Past WeekTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → At baseline assessment, end of each treatment session (weekly for 5 weeks post-baseline), 3-month follow-up, and 6-month follow up
  • EditedAnxiety and Depressive SymptomsTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up
  • AddedDepression SymptomsTime frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up.
  • AddedDistress ToleranceTime frame: At baseline assessment, 3-month follow-up, and 6-month follow-up
  • RemovedNonbinary Distal Stress (Nbi-DMSS )Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
  • RemovedProximal Minority Stress (Nbi-PMSS)Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
  • RemovedNonbinary Resilience (Nbi-RS)Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
  • RemovedSeverity of Nicotine DependenceTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
  • Time frame7-Day Point Prevalence AbstinenceAt the end of treatment intervention (approx. 10 weeks post-baseline) and at 3-month follow-up (T3; approx. 6 months post-baseline) → At the 3-month follow-up and 6-month follow-up
  • Time frameGender Minority StressAt baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → At baseline assessment, 3-month follow-up, and 6-month follow-up
Oct 8, 2026
Contact
Study contact now listed: added c•••@mgh.harvard.edu · •••0385; added s•••@bu.edu · •••6300. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Fenway Health · Boston, United StatesContact added e•••@fenwayhealth.org · •••6216Contact added E•••@mgh.harvard.eduContact added (no phone or email listed)
Oct 8, 2026
Title
Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals→Adapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Terminated→Recruiting
    Why stopped Reason for stopping removed
    3 sites changed recruiting status (2 now active, not recruiting, 1 now recruiting)
    Show 3 sites
    • Massachusetts General Hopsital · Boston, United Statesno status→Active, not recruiting
    • Boston University - Charles River Campus · Boston, United Statesno status→Active, not recruiting
    • Fenway Health · Boston, United Statesno status→Recruiting
    Primary completion Mar 18, 2025→Mar 31, 2027
    Study completion Mar 21, 2025→Aug 31, 2027
    Enrollment 3 (actual)→100 (estimated)
    Eligibility 2 inclusion criteria added, 1 removed; 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • Removedcurrent use of combustible cigarettes OR recent use of combustible cigarettes (defined as at least 5 cigarettes-per-day at some point within the past 6 months) OR current use of nicotine-containing e-cigarettes with use of combustible cigarettes in the past 6 months (defined as 5 cigarettes-per-day)
    • Addedcurrent use of combustible cigarettes (defined as self-reported 5 combustible cigarettes per day in any week in the past month and a carbon monoxide [CO] expired-air reading of ≥8ppm) OR current use of nicotine-containing e-cigarettes (defined by saliva cotinine level of ≥30ng/mL) with use of combustible cigarettes (5 cigarettes per day in any week in the past month)
    • Addeddesire to stop using tobacco products (defined by ≥5 on the Motivational Aspects of Smoking Cessation Questionnaire)
    Exclusion criteria
    • Editedcurrent interfering untreated or unstable major health condition that is event during screening (e.g., active maniabipolar, current psychosis)
    • Addedcurrent use of psychotherapy for smoking cessation
    • Addedparticipation in Aim 1a procedures.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAcceptabilityThrough the end of treatment intervention, approximately 10 weeks → Through the end of treatment intervention, approximately 6 weeks
    • DescriptionAcceptability: how it is measured was reworded
    Secondary outcomes 2 edited, 2 time frame changed, 2 added, 4 removed
    What changed in the outcomes
    • EditedAverage Number of Cigarettes Smoked Per Day In Thein the Past WeekTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → At baseline assessment, end of each treatment session (weekly for 5 weeks post-baseline), 3-month follow-up, and 6-month follow up
    • EditedAnxiety and Depressive SymptomsTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up
    • AddedDepression SymptomsTime frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up.
    • AddedDistress ToleranceTime frame: At baseline assessment, 3-month follow-up, and 6-month follow-up
    • RemovedNonbinary Distal Stress (Nbi-DMSS )Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
    • RemovedProximal Minority Stress (Nbi-PMSS)Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
    • RemovedNonbinary Resilience (Nbi-RS)Time frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
    • RemovedSeverity of Nicotine DependenceTime frame: At baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline)
    • Time frame7-Day Point Prevalence AbstinenceAt the end of treatment intervention (approx. 10 weeks post-baseline) and at 3-month follow-up (T3; approx. 6 months post-baseline) → At the 3-month follow-up and 6-month follow-up
    • Time frameGender Minority StressAt baseline assessment, end of treatment intervention (approx. 10 weeks post-baseline), and 3-month follow-up (T3; approx. 6 months post-baseline) → At baseline assessment, 3-month follow-up, and 6-month follow-up
    Contact Study contact now listed: added c•••@mgh.harvard.edu · •••0385; added s•••@bu.edu · •••6300. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fenway Health · Boston, United StatesContact added e•••@fenwayhealth.org · •••6216Contact added E•••@mgh.harvard.eduContact added (no phone or email listed)
    Title Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals→Adapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06654414
Responsible party
Conall O'Cleirigh (Director of Behavioral Medicine Program/Associate Professor, Massachusetts General Hospital) — Principal investigator
First posted
Oct 23, 2024
Start date
Sep 1, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Conall M O'Cleirigh, PhD
Contact
cocleirigh@mgh.harvard.edu
617-643-0385
Amelia Stanton, PhD
Contact
stantona@bu.edu
617-724-6300 ext. 111-136-0063
Conall M O'Cleirigh, PhD
principal investigator · Massachusetts General Hospital, Behavioral Medicine Program
Amelia Stanton, PhD
principal investigator · Boston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion